{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:57:43Z","timestamp":1790168263858,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2016R1A6A1A03011325"],"award-info":[{"award-number":["NRF-2016R1A6A1A03011325"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2021R1A2C1092739"],"award-info":[{"award-number":["NRF-2021R1A2C1092739"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biomaterials.2022.121911","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T02:43:43Z","timestamp":1668221023000},"page":"121911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer"],"prefix":"10.1016","volume":"291","author":[{"given":"Ramesh","family":"Duwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Hari","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Banstola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-169X","authenticated-orcid":false,"given":"Jee-Heon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-6570","authenticated-orcid":false,"given":"Jae-Hoon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simmyung","family":"Yook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib2","first-page":"1","article-title":"Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy","author":"Alhallak","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biomaterials.2022.121911_bib4","series-title":"The Making of Bispecific Antibodies, MAbs","first-page":"182","author":"Brinkmann","year":"2017"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121911_bib5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti\u2013PD\u20131 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN\u2013\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121911_bib6","first-page":"838","article-title":"Bispecific antibodies, drug discov","volume":"20","author":"Kontermann","year":"2015","journal-title":"Today Off."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib7","first-page":"290","article-title":"Bispecific T\u2013cell engagers for cancer immunotherapy, Immunol","volume":"93","author":"Huehls","year":"2015","journal-title":"Cell Biol."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib9","first-page":"22","article-title":"BiTE: teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr. Opin. Mol. Therapeut."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121911_bib10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J. Immunother."},{"issue":"5425","key":"10.1016\/j.biomaterials.2022.121911_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.285.5425.221","article-title":"The immunological synapse: a molecular machine controlling T cell activation","volume":"285","author":"Grakoui","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib12","first-page":"1","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol. Pharm"},{"key":"10.1016\/j.biomaterials.2022.121911_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121911_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2050","article-title":"Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells","volume":"12","author":"Thiery","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.immunol.19.1.375","article-title":"The immunological synapse","volume":"19","author":"Bromley","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib17","series-title":"CEA\/CD3 Bispecific Antibody MEDI-565\/AMG 211 Activation of T Cells and Subsequent Killing of Human Tumors Is Independent of Mutations Commonly Found in Colorectal Adenocarcinomas, MAbs","first-page":"1571","author":"Oberst","year":"2014"},{"issue":"289","key":"10.1016\/j.biomaterials.2022.121911_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib19","first-page":"273","article-title":"Catumaxomab, a rat\/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer","volume":"10","author":"Shen","year":"2008","journal-title":"Curr. Opin. Mol. Therapeut."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121911_bib20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121911_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121911_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40259-014-0091-4","article-title":"Multi-specific antibodies for cancer immunotherapy","volume":"28","author":"Jachimowicz","year":"2014","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm0904-887","article-title":"Cancer immunotherapy: breaking the barriers to harvest the crop","volume":"10","author":"Pardoll","year":"2004","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121911_bib28","first-page":"3372","article-title":"Human dendritic cells stimulated via TLR7 and\/or TLR8 induce the sequential production of Il\u201310, IFN\u2013\u03b3, and IL\u201317A by naive CD4+ T cells","volume":"182","author":"Lombardi","year":"2009","journal-title":"J. Immunol. Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/1061186X.2018.1474360","article-title":"Modulating T-cell-based cancer immunotherapy via particulate systems","volume":"27","author":"Truong","year":"2019","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14417-6","article-title":"Combined immunotherapy with anti-PDL-1\/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma","volume":"7","author":"Rigo","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01420-9","article-title":"AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR\/p38 signaling pathway","volume":"20","author":"Pokhrel","year":"2021","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121911_bib33","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biomaterials.2022.121911_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2019.10.047","article-title":"Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death","volume":"315","author":"Dai Phung","year":"2019","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib36","first-page":"229","article-title":"PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas, Ann","volume":"97","author":"Wang","year":"2018","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.biomaterials.2022.121911_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jiec.2020.11.015","article-title":"Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction","volume":"94","author":"Duwa","year":"2020","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.biomaterials.2022.121911_bib38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2016.01.050","article-title":"Immune responses to vaccines delivered by encapsulation into and\/or adsorption onto cationic lipid-PLGA hybrid nanoparticles","volume":"225","author":"Liu","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121911_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jconrel.2021.07.035","article-title":"p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer","volume":"337","author":"Garizo","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121911_bib40","first-page":"1","article-title":"Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches","author":"Hegde","year":"2021","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.biomaterials.2022.121911_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jiec.2019.06.050","article-title":"Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme","volume":"79","author":"Duwa","year":"2019","journal-title":"J. Ind. Eng. Chem."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2022.121911_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2007.03.012","article-title":"Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody","volume":"120","author":"Kocbek","year":"2007","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121911_bib43","article-title":"Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells","volume":"60","author":"Duwa","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2022.04.003","article-title":"Enhancement of blood\u2013brain barrier penetration and the neuroprotective effect of resveratrol","volume":"346","author":"Katila","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121911_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120031","article-title":"Drug\u2013loading capacity of polylactide\u2013based micro\u2013and nanoparticles\u2013Experimental and molecular modeling study","volume":"591","author":"Zatorska","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2022.121911_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2020.04.027","article-title":"Photo-triggered self-destructive ROS-responsive nanoparticles of high paclitaxel\/chlorin e6 co-loading capacity for synergetic chemo-photodynamic therapy","volume":"323","author":"Yang","year":"2020","journal-title":"J. Contr. Release"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4062\/biomolther.2022.015","article-title":"Bispecific antibody-bound T cells as a novel anticancer immunotherapy","volume":"30","author":"Cho","year":"2022","journal-title":"Biomol Ther"},{"issue":"26","key":"10.1016\/j.biomaterials.2022.121911_bib48","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.biomaterials.2013.05.006","article-title":"The effect of hydrophilic and hydrophobic structure of amphiphilic polymeric micelles on their transport in epithelial MDCK cells","volume":"34","author":"Yu","year":"2013","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/ejso.2000.1060","article-title":"Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers","volume":"27","author":"Kontani","year":"2001","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00002371-199402000-00002","article-title":"Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation","volume":"15","author":"Finke","year":"1994","journal-title":"J. Immunother. Emphas. Tumor Immunol."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib51","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1166\/jbn.2018.2619","article-title":"TLS11a aptamer\/CD3 antibody anti-tumor system for liver cancer","volume":"14","author":"Hu","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01564-4","article-title":"A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer","volume":"39","author":"Zhou","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.biomaterials.2022.121911_bib53","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"5891","key":"10.1016\/j.biomaterials.2022.121911_bib54","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121911_bib55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biomaterials.2022.121911_bib56","article-title":"Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Tabernero","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J. biotechnol. biomed"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib58","first-page":"62","article-title":"Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848, Cell","volume":"197","author":"Ahonen","year":"1999","journal-title":"Immunol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib59","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3389\/fimmu.2018.02982","article-title":"HMGN1 and R848 synergistically activate dendritic cells using multiple signaling pathways","volume":"9","author":"Alam","year":"2018","journal-title":"Front. Immunol."},{"issue":"75","key":"10.1016\/j.biomaterials.2022.121911_bib60","doi-asserted-by":"crossref","first-page":"40085","DOI":"10.1039\/C4RA05796A","article-title":"Preparation and evaluation of hypocrellin A loaded poly (lactic-co-glycolic acid) nanoparticles for photodynamic therapy","volume":"4","author":"Qi","year":"2014","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/02652048.2018.1453560","article-title":"Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells","volume":"35","author":"Patel","year":"2018","journal-title":"J. Microencapsul."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib62","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/am406012g","article-title":"Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy","volume":"6","author":"Vivek","year":"2014","journal-title":"ACS Appl. Mater."},{"key":"10.1016\/j.biomaterials.2022.121911_bib63","unstructured":"INVALID CITATION !!!)."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib64","article-title":"PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment","volume":"2","author":"Grenga","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib65","first-page":"1893","article-title":"Membranous and cytoplasmic expression of PD-L1 in ovarian cancer cells, Cell","volume":"43","author":"Qu","year":"2017","journal-title":"Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib66","first-page":"1","article-title":"Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells, Cell Commun","volume":"13","author":"Noh","year":"2015","journal-title":"Signals"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI96113","article-title":"Host expression of PD\u2013L1 determines efficacy of PD\u2013L1 pathway blockade\u2013mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biomaterials.2022.121911_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.colsurfb.2017.12.001","article-title":"Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin\u00ae\u2013conjugated PLGA\u2013PEG nanoparticles for drug delivery","volume":"162","author":"Badkas","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biomaterials.2022.121911_bib69","first-page":"461","article-title":"Toll-like receptor signaling pathways","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121911_bib70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib71","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","author":"Sch\u00f6n","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.canlet.2015.09.017","article-title":"TLR7\/8 agonists promote NK\u2013DC cross\u2013talk to enhance NK cell anti\u2013tumor effects in hepatocellular carcinoma","volume":"369","author":"Zhou","year":"2015","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2022.5449","article-title":"The TLR7\/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer","volume":"61","author":"Zhou","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121911_bib75","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121911_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/bs.acr.2018.05.003","article-title":"Nanotechnology approaches to improving cancer immunotherapy","volume":"139","author":"Hagan IV","year":"2018","journal-title":"Adv. Cancer Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib77","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/ijms23031350","article-title":"Targeted delivery of immunostimulatory CpG oligodeoxynucleotides to antigen-presenting cells in draining lymph nodes by stearic acid modification and nanostructurization","volume":"23","author":"Nagaoka","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2022.121911_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actbio.2020.07.063","article-title":"Immunoadjuvants for cancer immunotherapy: a review of recent developments","volume":"114","author":"Banstola","year":"2020","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib80","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib81","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biomaterials.2022.121911_bib82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"35","key":"10.1016\/j.biomaterials.2022.121911_bib83","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19865","article-title":"CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice","volume":"8","author":"Horn","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib84","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1080\/10717544.2017.1377317","article-title":"Single synchronous delivery of FK506-loaded polymeric microspheres with pancreatic islets for the successful treatment of streptozocin-induced diabetes in mice","volume":"24","author":"Pathak","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biomaterials.2022.121911_bib85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biomaterials.2017.10.049","article-title":"Tissue adhesive FK506\u2013loaded polymeric nanoparticles for multi\u2013layered nano\u2013shielding of pancreatic islets to enhance xenograft survival in a diabetic mouse model","volume":"154","author":"Pham","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2022.121911_bib86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2022.03.015","article-title":"Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy","volume":"344","author":"Cheng","year":"2022","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib87","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib88","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4161\/onci.22033","article-title":"How imiquimod licenses plasmacytoid dendritic cells to kill tumors","volume":"1","author":"Holcmann","year":"2012","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121911_bib89","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/jid.2014.194","article-title":"Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization","volume":"134","author":"Aspord","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121911_bib90","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/acs.biomac.0c00812","article-title":"Nanoparticles presenting potent TLR7\/8 agonists enhance anti-PD-L1 immunotherapy in cancer treatment","volume":"21","author":"Smith","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2022.121911_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-030-35723-8_4","article-title":"Cytotoxic CD8+ lymphocytes in the tumor microenvironment","author":"Iwahori","year":"2020","journal-title":"Tumor Microenvironment"},{"key":"10.1016\/j.biomaterials.2022.121911_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ T cells in tumor microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121911_bib94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/IR:24:2:201","article-title":"Regulation of tumor growth by IFN\u2013\u03b3 in cancer immunotherapy","volume":"24","author":"Beatty","year":"2001","journal-title":"Immunol. Res."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121911_bib95","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2164\/jandrol.111.015164","article-title":"A possible role for perforin and granzyme B in resveratrol\u2013enhanced radiosensitivity of prostate cancer","volume":"33","author":"Fang","year":"2012","journal-title":"J. Androl."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121911_bib96","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib97","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(01)00234-5","article-title":"The immunological synapse of CTL contains a secretory domain and membrane bridges","volume":"15","author":"Stinchcombe","year":"2001","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121911_bib98","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1445-5994.1995.tb02883.x","article-title":"Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore\u2013forming protein, perforin, and the serine protease, granzyme B","volume":"25","author":"Trapani","year":"1995","journal-title":"Aust. N. Z. J. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN\u2013\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121911_bib100","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.4049\/jimmunol.0901017","article-title":"Protumor vs antitumor functions of IL-17","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121911_bib101","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","article-title":"Current status of IL-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib102","first-page":"1","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121911_bib103","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/pharmaceutics13101696","article-title":"Liposomal resiquimod for enhanced immunotherapy of peritoneal metastases of colorectal cancer","volume":"13","author":"Pauli","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121911_bib104","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C","article-title":"Optimizing anti\u2013CD3 affinity for effective T cell targeting against tumor cells","volume":"32","author":"Bortoletto","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.biomaterials.2022.121911_bib107","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121911_bib108","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immun."},{"issue":"31","key":"10.1016\/j.biomaterials.2022.121911_bib109","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17232","article-title":"PD1 signal transduction pathways in T cells","volume":"8","author":"Arasanz","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121911_bib110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"10.1016\/j.biomaterials.2022.121911_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2021.109465","article-title":"Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy","volume":"202","author":"Liu","year":"2021","journal-title":"Mater. Des."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121911_bib112","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121911_bib113","first-page":"47","article-title":"Immunogenic cell death: a step ahead of autophagy in cancer therapy","volume":"3","author":"Gupta","year":"2021","journal-title":"J. cancer Immunol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222005518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222005518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:17:44Z","timestamp":1758907064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222005518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":113,"alternative-id":["S0142961222005518"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121911","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121911"}}